Portal hypertension is the leading cause of death and liver transplantation in cirrhosis. His work enabled the discovery of new therapeutic targets that were incorporated into clinical practice, reducing the mortality rate associated with this disease. Dr Bosch was decisive in supporting translational research in hepatology: in 1982, he founded one of the most prestigious laboratories in the world for evaluating and treating patients with portal hypertension, where many scientists from all over the world have been trained.
Jaume Bosch was a senior consultant for the Hepatology Service at Hospital Clínic Barcelona, the head of the IDIBAPS group, a professor at the University of Barcelona’s Faculty of Medicine, the scientific director of the CIBER of Hepatic and Digestive Diseases (CIBERehd) and president of the Spanish Association for the Study of the Liver (AEEH). In 2012, he received the Gold Medal of the Canadian Association for the Study of the Liver (CASL) and the Canadian Association of Gastroenterology. In 2013, he was awarded the Lilly Prize in the clinical research category. In 2014, he was named Doctor Honoris Causa by the University of Toulouse and in 2016, he received the same distinction from the University of Cluj-Napoca (Transylvania).
Most recently, he was an emeritus researcher in the IDIBAPS research group Liver vascular biology and participated in the event commemorating the performance of 1,000 TIPS procedures at Hospital Clínic Barcelona.
We at IDIBAPS join in the expressions of condolence to the family and friends of Jaume Bosch.
